Sung Lee

Sung Lee

Former Executive Vice President and Chief Financial OfficeratVir Biotechnology· In proxies 2023–2024

Pay in FY2024-64% from the year before · Vir Biotechnology stock -27.0% the same year

Sung Lee was paid $1.7M in FY2024 (Dec), down 64%. Vir Biotechnology stock fell 27.0% that year.

Pay$100 in the stock at the end of FY22 → $29
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 3 yr
    • Former Executive Vice President and Chief Financial Officer2023 – Present · 3 yrStock in role -52%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?